BCIQ Profiles

Company Profile Report

Kintai reveals preclinical validation for its microbiome-inspired small molecules, prioritizes obesity

Led by CEO Tak, Flagship Pioneering’s Kintai adds preclinical validation to its platform with obesity data

The first set of preclinical data from Kintai’s microbiome-derived small molecule platform supports the idea that manipulating the enteric signaling network with small molecules is one way to tap

Read the full 291 word article

How to gain access

Continue reading with a
two-week free trial.